Home/ Author / Drew Meredith
    Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Abbey Minogue

  • Alex Lennard

  • Amanda Mark

  • Andrew Lockhart

  • Australian Ethical

  • Bob Desmond

  • Brad Tank

  • Complii

  • Contributor

  • David Chaplin

  • David Simon

  • Drew Meredith

  • Duncan MacInnes

  • Eleanor Moriarty

  • Eleece Quilliam

  • Emanual Datt

  • Francis Gannon

  • Francyne Mu

  • George Lin

  • Giselle Roux

  • Greg Bright

  • HMC Capital

  • Helen Nan

  • Henry Maxey

  • Invesco

  • Ishan Dan

  • Jacquelyn Mann

  • James Dunn

  • Jamie Dannhauser

  • Jamie Nemtsas

  • Jasmine Yeo

  • Jaxon King

  • Joe Millward

  • Jonathan Ruffer

  • Kevin Pelham

  • Kevin Toohey

  • Kim Ivey and Michael Armitage

  • Kristina Hooper

  • Lachlan Buur-Jensen

  • Lachlan Maddock

  • Lauren French

  • Laurence Parker-Brown

  • Lisa Uhlman

  • Luke Laretive

  • Matthew O'Leary

  • Michael Armitage

  • Michael Block

  • Michael McQueen

  • Mishan Dahia

  • NIcholas Ali

  • Neuberger Berman

  • Nicholas Way

  • Nick Hatzis

  • Nick Langley

  • Nicki Bourlioufas

  • Nigel Baker

  • Owen Raszkiewicz

  • Peter McPhee

  • Peter Vala

  • Phil Strano

  • Pzena Investment Management

  • Rob Perrone, Eric Marais & Shane Woldendorp

  • Rob Prugue

  • Roy Keenan

  • Sean Graham

  • Staff Writer

  • Steve Russell

  • Tahn Sharpe

  • The Inside Adviser

  • Tim Kruger

  • Tom King

  • Will Arnost

  • Yarra Capital Management

  • All Categories

  • All Categories

  • Equities

  • In Practice

  • Growth assets

  • Asset Allocation

  • ESG

  • Economics

  • Defensive assets

  • Compliance

  • Advice

  • News

  • Launches

  • Alternatives

  • Retirement

  • Legislation

  • Fixed Income

  • Intel

  • Opinion

  • SMSF

  • Markets

  • Daily Market Update

  • Asset management

  • Industry

  • Regulation

  • Education

  • Focus

  • Investing 101

  • M&A

  • Super

  • Uncategorized

  • Analysis

  • SMSFs

Drew Meredith

Drew is editor of The Inside Network's publications and a principal adviser at Wattle Partners.

Drew Meredith results

Disruptive innovation delivered a 90% return for ARK

The Dr Cathie Wood-led ARK Investment Management is facing a different kind of pressure as 2020 draws to a close. According to Bloomberg, ARK’s ETF distributor, Resolute Investment Managers, is seeking to exercise an option acquired in 2016 to buy a controlling stake in the business. The ARK Invest strategy has been a clear winner…

Drew Meredith | 19th Nov 2020 | More
Crown (ASX:CWN) shutdown

ASX delivers third straight increase but weak open ahead, Crown (ASX:CWN) shutdown, anaemic wage growth The ASX200 (ASX:XJO) experienced another positive, albeit somewhat mixed, day with the banking sector (+1.7%) forcing the market higher by 0.5%.  The travel sector was the key detractor as an outbreak in South Australia combined with profit taking hitting confidence. …

Drew Meredith | 18th Nov 2020 | More
Charter Hall (ASX:CHC) and Centuria (ASX:CIP) continue to acquire

ASX up and running, to open weaker, Charter Hall (ASX:CHC) and Centuria (ASX:CIP) continue to acquire The ASX (ASX:ASX) managed to open on time Tuesday after significant issues to begin the week, though management flagged some ‘settlement’ issues had also arisen, sending the share price 1.5% lower.  In terms of the ASX200 (ASX:XJO) it was…

Drew Meredith | 17th Nov 2020 | More
Moderna (NYSE:MRNA) vaccine 94% effective

Sharemarket to open strongly, Moderna (NYSE:MRNA) vaccine 94% effective, ASX (ASX:ASX) system failure, US markets hit record The S&P/ASX200 (ASX:XJO) managed just 25 minutes of trade this morning before its new settlement system failed, closing down the market for the day.  Before the shutdown it was a positive start, the market finished 1.2% higher on the…

Drew Meredith | 16th Nov 2020 | More
Can credit replace lost dividends in a zero-rate world?

As 2020 comes to a close, investors of all kinds are faced with what seems to be a once-in-a-lifetime dilemma; how to generate an income in a zero-rate world. Despite clear evidence that investing in stocks solely for their income has generally detracted from, rather than added to, long-term returns, the nature of the Australian…

Drew Meredith | 16th Nov 2020 | More
  • ASX stocks down 0.2%

    ASX stocks down 0.2%, ‘Go long’ says star investor Bill Ackman, Ramsay Healthcare (ASX:RHC) reports, positive open ahead The ASX200 (ASX:XJO) fell for the second straight day finishing down 0.2% but managed to add 3.2% for the week.  The reasons were clear, positive news on a COVID-19 vaccine coming from Pfizer (NYSE:PFE) sent beaten down…

    Drew Meredith | 15th Nov 2020 | More
    ASX to open lower, Telstra (ASX:TLS) outperforms

    ASX 200 (ASX:XJO) falls 0.5%, Telstra (ASX:TLS) outperforms, US market falls ASX to open lower It was a mixed day for the ASX200 (ASX:XJO) taking a breather after what has been a hectic few days.  Most sectors were down, with telecommunications and consumer discretionary the standouts, adding 1.9% and 1.0% on company specific news.  Wesfarmers…

    Drew Meredith | 12th Nov 2020 | More
    Six-member SMSFs one step closer

    It’s been a long time coming, yet it may finally be here. The arbitrary cap on the allowable number of SMSF members, limiting funds to just four people, appears set to be lifted. The legislation has been delayed due to the pandemic but the proposal to increase the maximum number of members from four to…

    Drew Meredith | 12th Nov 2020 | More
    Rotation rally continues, ASX 1.7% higher

    Rotation rally continues, ASX 1.7% higher, Commonwealth Bank (ASX:CBA) reports, US markets mixed, ASX to open positive The rotation rally continued on Wednesday as investors adjusted portfolios to what appears to be a sooner than expected return to normal. Every sector finished higher, with COVID beneficiaries including Consumer Discretionary (+0.7%) and healthcare (0.2%) among the ‘weakest’….

    Drew Meredith | 11th Nov 2020 | More
    ASX rallies on vaccine news

    ASX rallies on vaccine news, cyclical rotation in full flight, Westfield (ASX:URW) jumps 43.5% The ASX 200 (ASX:XJO) finished just 0.7% above open despite trading as much as 2.5% higher during the day on news of Pfizer’s (NYSE:PFE) successful vaccine trials.  For those interested, reports suggest that the treatment has 90% efficacy in protecting from…

    Drew Meredith | 11th Nov 2020 | More
    1 54 55 56 57 58 72
    Our Authors
    Popular
  • Popular posts: